Share

May 07, 2019; 92 (19) Editorial

Recognizing autoimmune encephalitis as a cause of seizures

Treating cause and not effect

Jeffrey W. Britton, Josep Dalmau
First published April 12, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007444
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
526

Share

Article Information

vol. 92 no. 19 877-878
DOI: 
https://doi.org/10.1212/WNL.0000000000007444
PubMed: 
30979858
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 12, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Jeffrey W. Britton, MD and
    2. Josep Dalmau, MD
  1. Jeffrey W. Britton, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Unpaid co-investigator clinical trials: -A Randomized Double Blind Placebo Controlled Study of IVIG in Patients with Voltage Gated Potassium Channel Complex Antibody Associated Autoimmune Epilepsy - Grifols Pharmaceuticals -A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately- controlled seizures- Greenwich Pharmaceuticals - An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes - Greenwich Pharmaceuticals

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mr. and Mrs. David Hawk charitable gift for epilepsy research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Josep Dalmau, MD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate

    Patents:

    1. Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Advance Medical

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. -NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -Fundacio CELLEX

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun

    Royalty Payments, Technology or Inventions:

    1. Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Epilepsy (J.W.B.) and ICREA and Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic (J.D.), Universitat de Barcelona, Spain; and Department of Neurology(J.D.), University of Pennsylvania, Philadelphia.
  1. Correspondence
    Dr. Britton britton.jeffrey{at}mayo.edu
View Abstract

Article usage

Article usage: April 2019 to October 2023

AbstractFullPdfSource
Apr 2019947079Highwire
May 2019878148114Highwire
Jun 20193202429Highwire
Jul 20192001715Highwire
Aug 20191182216Highwire
Sep 20191682111Highwire
Oct 20191321023Highwire
Nov 20191831719Highwire
Dec 20191341023Highwire
Jan 20201611227Highwire
Feb 2020150426Highwire
Mar 202088315Highwire
Apr 2020126412Highwire
May 2020103617Highwire
Jun 2020189611Highwire
Jul 202076107Highwire
Aug 20208187Highwire
Sep 202080411Highwire
Oct 20209838Highwire
Nov 20205726Highwire
Dec 20207404Highwire
Jan 20216044Highwire
Feb 20215636Highwire
Mar 20216738Highwire
Apr 20219635Highwire
May 20213421Highwire
Jun 20216231Highwire
Jul 20213500Highwire
Aug 20216221Highwire
Sep 20212341Highwire
Oct 20211922Highwire
Nov 20213200Highwire
Dec 20212112Highwire
Jan 20222331Highwire
Feb 20224200Highwire
Mar 20221800Highwire
Apr 20223020Highwire
May 20222710Highwire
Jun 20221733Highwire
Jul 20222601Highwire
Aug 20222921Highwire
Sep 20224011Highwire
Oct 20222753Highwire
Nov 20224620Highwire
Dec 20222510Highwire
Jan 20233322Highwire
Feb 20232400Highwire
Mar 20232000Highwire
Apr 20231401Highwire
May 20231400Highwire
Jun 20231301Highwire
Jul 20232010Highwire
Aug 20231000Highwire
Sep 20231911Highwire
Oct 20231300Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles